BrainEver successfully raised €33 million in a Series B funding round to initiate a crucial ALS clinical trial, reflecting strong investor confidence in its innovative therapeutic approach.

Information on the Target

BrainEver is a French biotechnology company specializing in the development of innovative treatments for neurodegenerative diseases. Established in 2015 by renowned neuroscientist Professor Alain Prochiantz and serial entrepreneur Bernard Gilly, the company focuses on translating groundbreaking research into potential therapeutic applications for conditions affecting the central nervous system. The company's lead candidate, a homeoprotein called Engrailed 1, is currently undergoing preclinical validation and is expected to enter clinical development next year for the treatment of amyotrophic lateral sclerosis (ALS).

Recently, BrainEver successfully closed a Series B funding round, raising €33 million. This investment comes at a challenging time for French biotech firms and will enable the company to initiate its first clinical trial involving ALS patients in Europe, thus marking a significant step towards human validation of their therapeutic approach.

Industry Overview in France

The biotechnology sector in France has been under increasing strain in recent years due to various economic challenges. Despite the funding difficulties, there remains a robust commitment to ad